WCN26-3995 Chronic Thrombotic Microangiopathy Induced by Long-Term Imatinib Therapy: A Case Report

Imatinib, a tyrosine kinase inhibitor(TKI) targeting platelet-derived growth factor receptor (PDGFR), BCR-ABL and c-KIT, is generally regarded as a well-tolerated agent. However, prolonged inhibition of PDGFR signaling can lead to endothelial dysfunction and causes thrombotic microangiopathy (TMA) in rare cases. We report a case of chronic TMA that developed after 17 years of low-dose imatinib therapy for chronic myeloid leukemia (CML), emphasizing the potential for cumulative endothelial injury associated with extended exposure.